Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Loading...
Type
Article
Change log
Authors
Spencer, Sarah
Kostel Bal, Sevgi
Egner, William
Abstract
Abstract: IL-6 excess is central to the pathogenesis of multiple inflammatory conditions and this is targeted in clinical practice by immunotherapy that blocks the IL-6 receptor encoded by IL6R. We describe two patients with homozygous mutations in IL6R who presented with recurrent infections, abnormal acute phase responses, elevated IgE, eczema, and eosinophilia. This study identifies a novel primary immunodeficiency, clarifying the contribution of IL-6 to the phenotype of patients with mutations in IL6ST, STAT3 and ZNF341, genes encoding different components of the IL-6 signalling pathway, and alerts us to the potential toxicity of drugs targeting the IL-6R.
Description
Keywords
Adolescent, Adult, Child, Child, Preschool, Female, HEK293 Cells, Humans, Immunologic Deficiency Syndromes, Infant, Newborn, Inflammation, Male, Receptors, Interleukin-6
Journal Title
Journal of Experimental Medicine
Conference Name
Journal ISSN
1540-9538
1540-9538
1540-9538
Volume Title
216
Publisher
Rockefeller University Press
Publisher DOI
Sponsorship
Medical Research Council (MR/L006197/1)
Cancer Research UK (CB4270)
Medical Research Council (MR/L019027/1)
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC)
Cancer Research UK (CB4270)
Medical Research Council (MR/L019027/1)
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC)
J.E.D.T. is supported by the MRC (RG95376 and MR/L006197/1). KB is supported by the European Research Council (ERC StG 310857) and the Austrian Science Fund (P29951-B30). This work is supported, in part, by the intramural research program of the NIAID, NIH. A.J.T. is supported by the Wellcome Trust (104807/Z/14/Z) and the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. KGCS is supported by the Medical Research Council (program grant MR/L019027) and is a Wellcome Investigator. M.G. and S.T. are supported in part by Cancer Research UK. RCA and MT are supported by a DOC fellowship of the Austrian Academy of Sciences. This research was made possible through access to the data and findings generated by two pilot studies for the 100,000 Genomes Project. The enrolment for one pilot study was coordinated by the NIHR BioResource (preprint from doi: https://doi.org/10.1101/507244) and the other by Genomics England Limited (GEL), a wholly owned company of the Department of Health in the UK. Over 90% of participants in the pilot studies have been enrolled in the NIHR BioResource. These pilot studies were mainly funded by grants from the National Institute for Health Research (NIHR) in England to the University of Cambridge and GEL, respectively. Additional funding was provided by the BHF, MRC, NHS England, the Wellcome Trust, amongst many other funders. The pilot studies use data provided by patients and their close relatives and collected by the NHS and other healthcare providers as part of their care and support. We thank all volunteers for their participation, and also gratefully acknowledge NIHR Biomedical Research Centres, NIHR BioResource Centres, NHS Trust Hospitals, NHS Blood and Transplant and staff for their contribution. ST is on the scientific advisory board for Ipsen, and is a consultant for Kallyope Inc. The authors declare no competing financial interests.